Stakeholders Point to Three Forces Behind Faster Drug and Vaccine Development
The push to speed clinical development has moved from theory to operational reality. The COVID-19 pandemic proved that rapid trial activation, compressed review cycles, and coordinated decision-making can deliver medicines and vaccines without sacrificing safety, provided the system is built to move in step. In a qualitative interview study spanning 25 stakeholders, the clearest drivers of acceleration clustered around three domains: alignment of stakeholders, innovative research design and processes, and financing.
The message from participants was not simply that development can move faster. It can, but only when the surrounding structure stops working against it.
Alignment Across Regulators, Sponsors, and Public Health Bodies
Alignment emerged as the first and most repeated force shaping acceleration. Interviewees drawn from pharmaceutical companies, the European Medicines Agency, national competent authorities in the EU, research and clinical development organizations, non-governmental organizations, and the World Health Organization described speed as a product of shared expectations rather than raw urgency alone. When stakeholders move with a common understanding of goals, evidence requirements, and decision thresholds, trials can advance with fewer pauses and less duplication.
The practical meaning is straightforward. A sponsor can design a study rapidly, but if regulators, ethics bodies, and clinical sites interpret the process differently, time is lost in translation. Harmonized expectations reduce avoidable rework, shorten back-and-forth exchanges, and make protocol execution more predictable across countries and institutions. In vaccine and drug development, where delays can ripple through manufacturing, enrollment, and post-approval access, even small gains in coordination can translate into meaningful public health benefit.
Participants also pointed to the importance of communication between institutions that often operate in parallel rather than in concert. Better exchange among stakeholders does not eliminate scientific uncertainty, but it does reduce administrative drift. In accelerated development, the difference between a coordinated network and a fragmented one is measured in months, not abstractions.
Trial Design Changes Can Compress Timelines Without Abandoning Rigor
Innovative research design and processes formed the second driver. Stakeholders described acceleration as dependent on methods that preserve scientific validity while trimming avoidable inefficiency. That includes study designs and operational approaches that allow evidence generation to proceed with less redundancy and more responsiveness to emerging data.
This theme fits a broader clinical reality. Traditional development pathways were built for a slower era, one in which sequential steps were often treated as the safest default. Pandemic-era experience challenged that assumption and showed that faster recruitment, tighter coordination, and more adaptive operational planning can be compatible with robust evidence generation. The central issue is not whether speed is possible, but whether the system is willing to adopt methods that reflect modern trial logistics and regulatory science.
One of the most concrete barriers raised in the interviews was the complexity of the Clinical Trials Information System submission process. Bureaucratic burden does not merely inconvenience sponsors; it can slow site activation, complicate cross-border work, and discourage efficient multicenter collaboration. When submission pathways are opaque or technically cumbersome, even well-designed trials lose momentum before a single participant is enrolled.
European disharmony in trial practice, regulations, and guidance also surfaced as a recurring obstacle. Differences across jurisdictions create friction for investigators and sponsors trying to run studies at scale. Where acceleration depends on synchronized execution, uneven rules act like a drag on the entire process.
Financing Shapes Which Diseases Benefit from Speed
Funding was the third theme, and it carried a particularly sharp equity concern. Stakeholders did not frame financing as a generic enabler alone. They linked it to which diseases attract accelerated development in the first place, and which remain stranded in slower, under-resourced pathways.
Financial neglect for poverty-related diseases stood out as a structural barrier. Faster development is often easiest to achieve where commercial incentives are strongest, where development networks are already mature, and where capital can be mobilized quickly. Diseases concentrated in poorer populations do not benefit equally from that model. Without deliberate financing mechanisms, acceleration risks becoming selective rather than systemwide, leaving high-burden conditions behind because they are less attractive to market forces.
The implication reaches beyond the balance sheet. Development speed is not neutral when the financial architecture determines which programs survive long enough to mature. A funding system that rewards only commercially promising areas will accelerate some medicines while preserving delay for the conditions that most depend on public or philanthropic support.
What the Pandemic Proved About Speed, and What Still Blocks It
COVID-19 demonstrated that expedited drug and vaccine development can be both fast and safe when urgency is matched by coordination. This study places that lesson in a broader policy frame, showing that acceleration depends on three linked conditions: stakeholder alignment, workable research design, and financing that does not exclude lower-profit disease areas.
The interviews also reveal where progress still stalls. Fragmentation of effort drains momentum. Conflicting guidance wastes time. Administrative burden slows multicenter work. And inequitable funding priorities leave some diseases outside the acceleration agenda entirely. Each of those barriers is operational rather than abstract, which makes them possible to address through policy and governance rather than scientific discovery alone.
For regulators and policymakers, the clinical implication is direct. Faster development will not be sustained by emergency pressure alone. It requires systems that reduce technical friction, simplify cross-border trial conduct, and support collaboration among the groups that actually determine whether a study opens, enrolls, and delivers results. Without that infrastructure, acceleration will remain episodic, strongest in crises and weakest where need is greatest.